

WHAT IS CLAIMED IS:

1. A compound selected from the group consisting of: [3-(2-acetylaminooethyl)-2-methyl-1H-indol-5-yl]-carbamic acid methyl ester; [3-(2-acetylaminooethyl)-2-phenyl-1H-indol-5-yl]-carbamic acid methyl ester; [3-(3-acetylaminoprop-1-yl)-1H-indol-5-yl]-carbamic acid methyl ester; N-[2-(5-methoxycarbonylamino-1H-indol-3-yl)-ethyl]-succinamic acid; [3-(2-acetylaminooethyl)-1H-indol-5-yl]-carbamic acid allyl ester; [3-(2-acetylaminooethyl)-1H-indol-5-yl]-carbamic acid 3-hydroxyprop-1-yl ester; [3-(2-acetylaminooethyl)-4-(1-methoxyethyl)-1-methyl-1H-indol-5-yl]-carbamic acid methyl ester; N-[3-(2-acetylaminooethyl)-1H-indol-5-yl]-acetamide; [3-(2-acetylaminooethyl)-1-benzyl-1H-indol-5-yl]-carbamic acid methyl ester; (1-oxo-2,3,4,9-tetrahydro-1H- β -carbolin-6-yl)-carbamic acid methyl ester; [3-(2-acetylaminooethyl)-2-bromo-1H-indol-5-yl]-carbamic acid methyl ester; and [3-(2-propionylaminoethyl)-1H-indol-5-yl]-carbamic acid methyl ester.
- 15 2. The compound according to Claim 1, wherein the compound is 3-(2-acetylaminooethyl)-2-methyl-1H-indol-5-yl]-carbamic acid methyl ester.
3. The compound according to Claim 1, wherein the compound is [3-(2-acetylaminooethyl)-1H-indol-5-yl]-carbamic acid allyl ester.
- 20 4. The compound according to Claim 1, wherein the compound is [3-(2-acetylaminooethyl)-1-benzyl-1H-indol-5-yl]-carbamic acid methyl ester.
5. The compound according to Claim 1, wherein the compound is (1-oxo-2,3,4,9-tetrahydro-1H- β -carbolin-6-yl)-carbamic acid methyl ester.
- 25 6. The compound according to Claim 1, wherein the compound is [3-(2-acetylaminooethyl)-2-bromo-1H-indol-5-yl]-carbamic acid methyl ester.

7. The compound according to Claim 1, wherein the compound is [3-(2-propionylamino-ethyl)-1H-indol-5-yl]-carbamic acid methyl ester.

5 8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of: [3-(2-acetylamino-ethyl)-2-methyl-1H-indol-5-yl]-carbamic acid methyl ester; [3-(2-acetylamino-ethyl)-2-phenyl-1H-indol-5-yl]-carbamic acid methyl ester; [3-(3-acetylamino-prop-1-yl)-1H-indol-5-yl]-carbamic acid methyl ester; N-[2-(5-methoxycarbonylamino-1H-indol-3-yl)-ethyl]-succinamic acid; [3-(2-acetylamino-ethyl)-1H-indol-5-yl]-carbamic acid allyl ester; [3-(2-acetylamino-ethyl)-1H-indol-5-yl]-carbamic acid 3-hydroxy-prop-1-yl ester; [3-(2-acetylamino-ethyl)-4-(1-methoxy-ethyl)-1-methyl-1H-indol-5-yl]-carbamic acid methyl ester; N-[3-(2-acetylamino-ethyl)-1H-indol-5-yl]-acetamide; [3-(2-acetylamino-ethyl)-1-benzyl-1H-indol-5-yl]-carbamic acid methyl ester; (1-oxo-2,3,4,9-tetrahydro-1H-β-carbolin-6-yl)-carbamic acid methyl ester; [3-(2-acetylamino-ethyl)-2-bromo-1H-indol-5-yl]-carbamic acid methyl ester; and [3-(2-propionylamino-ethyl)-1H-indol-5-yl]-carbamic acid methyl ester.

10

15

9. The pharmaceutical composition according to Claim 8, wherein the compound is 3-(2-acetylamino-ethyl)-2-methyl-1H-indol-5-yl]-carbamic acid methyl ester.

20

10. The pharmaceutical composition according to Claim 8, wherein the compound is [3-(2-acetylamino-ethyl)-1H-indol-5-yl]-carbamic acid allyl ester.

25

11. The pharmaceutical composition according to Claim 8, wherein the compound is [3-(2-acetylamino-ethyl)-1-benzyl-1H-indol-5-yl]-carbamic acid methyl ester.

12. The pharmaceutical composition according to Claim 8, wherein the compound is (1-oxo-2,3,4,9-tetrahydro-1H-β-carbolin-6-yl)-carbamic acid methyl ester.

13. The pharmaceutical composition according to Claim 8, wherein the compound is [3-(2-acetylamino-ethyl)-2-bromo-1H-indol-5-yl]-carbamic acid methyl ester.

14. The pharmaceutical composition according to Claim 8, wherein the compound is [3-(2-propionylamino-ethyl)-1H-indol-5-yl]-carbamic acid methyl ester.